Amylyx Q2 net loss $54.1M ($0.93/shr); ALBRIOZA launched in Canada; FDA PDUFA Sept 29

Amylyx Pharmaceuticals, Inc.

2022-Q2 EPS reported -$1.85

Net loss $54.1M vs $21.9M in Q2 2021; R&D $24.3M, G&A $30.0M; no product revenue.
Cash & equivalents $206.7M at June 30, down from $255.2M at March 31, 2022.
ALBRIOZA (AMX0035) commercially launched in Canada on July 29, 2022.
FDA AdCom meeting Sept 7, 2022; PDUFA decision date Sept 29, 2022 for ALS NDA.
EU MAA under review; decision expected first half 2023; commercial prep underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.